RFM
ZYNE

Royal Fund Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Royal Fund Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-50
Closed – – 610
2020
Q1 		$0 Hold
50
– – ﹤0.01% 776
2019
Q4 		$0 Buy
+50
New +$342 ﹤0.01% 724
2018
Q3 		– Sell
-25
Closed – – 679
2018
Q2 		$0 Buy
+25
New +$256 ﹤0.01% 659

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royal Fund Management's ZYNE Position: Q2 2020 in Review

Royal Fund Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 50 shares.

Royal Fund Management first reported a position in ZYNE in Q2 2018 and held it in 3 quarters. The position peaked at $0 in Q1 2020. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

  • Royal Fund Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
  • Royal Fund Management sold 50 Zynerba Pharmaceuticals, Inc shares in Q2 2020.
  • Royal Fund Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2018 and held it in 3 quarters.
  • Royal Fund Management's Zynerba Pharmaceuticals, Inc position peaked at $0 in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.